• BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Shilpa Medicare gains on launching generic cancer drug
(13:14, 30 Jun 2020)

The drug maker on Tuesday (30 June) launched the Indian branded generic of Axitinib, an tyrosine kinase inhibitor drug with a brand name Axishil.

Axishil is available as 1 mg & 5 mg tablets in pack of 14 tablets in one bottle. It is used to treat patients suffering from advanced renal cell carcinoma (RCC). Currently the monthly therapy cost of innovator is approximately Rs 1.66 lakh and with the launch of Axishil, monthly cost of treatment will be reduced to Rs 14,940.

Axishil is being launched to provide global quality Indian Brand with greater affordability to cancer patients. Today there are around 17,000 to 21,000 new patients in India who needs Axitinib and can be benefited by Axishil tablets, said Sundeip Bhatia, business head formulations India.

Shilpa Medicare is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates.

The drug maker's consolidated net profit surged 248.7% to Rs 55.06 crore on 36.6% jump in net sales to Rs 236.85 crore in Q3 December 2019 over Q3 December 2018.

Powered by Capital Market - Live News

DB (International) Stock Brokers Limited: SEBI Reg. No.-INZ000179035 / CDSL : IN-DP-CDSL-266-2004 MCX-SX:INE 260643233/21500(CD)
Daga Commodities Private Limited: SEBI Reg. No. INZ000028833
Investor Grievances Email ID: compliance@dbonline.in & investors@dbonline.in
Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and content powered by C-MOTS Infotech( ISO 9001:2015 certified )
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Attention Investors ::
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries